Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis

Bibliografske podrobnosti
Main Authors:	Ogdie, A, de Vlam, K, Bushmakin, A, Cappelleri, J, Mease, P, Fleischmann, R, Taylor, P, Azevedo, V, Fallon, L, Maniccia, A, Woolcott, J
Format:	Conference item
Izdano:	Wiley 2018

Podobne knjige/članki

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
od: de Vlam, K, et al.
Izdano: (2018)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
od: de Vlam, K, et al.
Izdano: (2021)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
od: Taylor, P, et al.
Izdano: (2019)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
od: de Vlam, K, et al.
Izdano: (2022)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
od: Taylor, PC, et al.
Izdano: (2020)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
od: Iain B McInnes, et al.
Izdano: (2020-02-01)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
od: Dougados, M, et al.
Izdano: (2020)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
od: Dougados, M, et al.
Izdano: (2022)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
od: Philip J. Mease, et al.
Izdano: (2024-01-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
od: Maxime Dougados, et al.
Izdano: (2022-11-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
od: Gladman, DD, et al.
Izdano: (2022)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
od: Daniela Graham, et al.
Izdano: (2021-04-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
od: Coates, L, et al.
Izdano: (2021)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
od: Taylor, P, et al.
Izdano: (2022)

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis
od: Taylor, PC, et al.
Izdano: (2021)

Measuring outcomes in psoriatic arthritis
od: Ogdie, A, et al.
Izdano: (2020)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
od: Peter C. Taylor, et al.
Izdano: (2022-07-01)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
od: Alexis Ogdie, et al.
Izdano: (2024-09-01)

Psoriatic arthritis - Tofacitinib as a new treatment
od: Marta Skorupska, et al.
Izdano: (2024-06-01)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
od: Philip J Mease, et al.
Izdano: (2019-06-01)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
od: Nash, P, et al.
Izdano: (2018)

Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
od: Kristensen, LE, et al.
Izdano: (2023)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
od: Philip J Mease, et al.
Izdano: (2019-06-01)

Psoriatic arthritis
od: FitzGerald, O, et al.
Izdano: (2021)

Classification and outcome measures for psoriatic arthritis
od: Leung, Y, et al.
Izdano: (2018)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
od: Helliwell, P, et al.
Izdano: (2018)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
od: Burmester, GR, et al.
Izdano: (2023)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
od: Nash, P, et al.
Izdano: (2020)

Search for predictors of achieving minimal disease activity during tofacitinib therapy in patients with psoriatic arthritis
od: L. D. Vorobyova, et al.
Izdano: (2023-12-01)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
od: Ogdie, A, et al.
Izdano: (2023)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
od: Kevin L. Winthrop, et al.
Izdano: (2022-12-01)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
od: Peter Nash, et al.
Izdano: (2018-11-01)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
od: Lars E. Kristensen, et al.
Izdano: (2023-02-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
od: E. Yu. Loginova, et al.
Izdano: (2020-06-01)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
od: Nash, P, et al.
Izdano: (2021)

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
od: Lars Erik Kristensen, et al.
Izdano: (2023-06-01)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
od: Gerd R. Burmester, et al.
Izdano: (2023-07-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
od: E. E. Gubar, et al.
Izdano: (2021-05-01)

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis
od: Victoria Navarro-Compán, et al.
Izdano: (2024-05-01)

Psoriatic arthritis: prospects for the future
od: Hackett, S, et al.
Izdano: (2022)